Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. Interested parties are encouraged to register for the upcoming investor call today at 4:30 PM ET, where detailed findings will be discussed. https://zoom.us/webinar/register/3117176913600/WN_Ev_1s7l2RUKmIQJNdko5iA Key Findings: Efficacy in Early AD Patients : In patients with early AD (MMSE 21-24), Buntanetap showed a statistically significant dose-response in ADAS-Cog11 scores, with a -3.3 points improvement over baseline and -2.3 points improvement from placebo. APOE4 Carrie
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Files Patent for New Composition of Matter for BuntanetapGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease DataGlobeNewswire
- Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference® 2024 [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 6/21/24 - Form S-8
- 6/13/24 - Form 8-K
- 6/11/24 - Form 8-K
- ANVS's page on the SEC website